雅本化學(300261.SZ):2024年度預虧1.85億元-2.65億元
格隆匯1月21日丨雅本化學(300261.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤虧損1.85億元–2.65億元,虧損比上年同期增加124.80%-222.02%;扣除非經常損益後的淨利潤虧損2.07億元–2.87億元,虧損比上年同期增加97.32%-173.57%。
報吿期內,農化市場景氣度低位,公司多年經營的某核心農藥產品市場競爭加劇,受終端市場產品價格下跌等不利因素影響,該農藥中間體銷售價格明顯下滑;同時,公司農藥、醫藥創新中間體業務拓展受制於客户商業化生產的節奏安排,尚處於立項、建設或產能爬坡階段,新項目對公司當期業績未能產生積極影響。鑑於此,公司盈利能力相較於去年同期有所下降。
公司2024年度非經常性損益約為人民幣2,200萬元,主要系公允價值變動收益和政府補助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.